Last updated: September 2, 2026
Efgartigimod alfa-fcab, marketed by argenx as VYVGART and VYVGART Hytrulo, has developed from a single-indication biologic into the company’s primary commercial asset. U.S. approval covers generalized myasthenia gravis, while VYVGART Hytrulo also covers chronic inflammatory demyelinating polyneuropathy. Product sales increased from $472 million in 2022 to approximately $1.2 billion in 2023 and approximately $2.2 billion in 2024, according to argenx financial disclosures.[1][2]
The principal market drivers are rapid neurologist adoption, expansion into CIDP, subcutaneous administration, repeat treatment cycles, and international launches. The main risks are concentration in one molecule, competition from other neonatal Fc receptor inhibitors, payer management, treatment sequencing, and eventual biosimilar or follow-on competition.
What is efgartigimod alfa-fcab and how does VYVGART work?
Efgartigimod alfa-fcab is an engineered human IgG1 Fc fragment that binds the neonatal Fc receptor, or FcRn. FcRn normally protects circulating IgG from lysosomal degradation. By reducing FcRn-mediated recycling, efgartigimod lowers pathogenic IgG antibodies.
The mechanism is relevant to antibody-mediated autoimmune diseases. In generalized myasthenia gravis, disease-driving autoantibodies disrupt neuromuscular transmission. In CIDP, pathogenic antibodies contribute to peripheral nerve dysfunction in a subset of patients.
VYVGART is administered intravenously. VYVGART Hytrulo combines efgartigimod alfa with recombinant human hyaluronidase PH20 and is administered subcutaneously. The Hytrulo formulation reduces administration time and supports treatment outside an infusion center.
Key product and regulatory milestones
| Date |
Milestone |
| December 2021 |
FDA approves VYVGART for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.[3] |
| December 2021 |
FDA grants biologic reference-product exclusivity for the original VYVGART approval. |
| June 2023 |
FDA approves VYVGART Hytrulo for adults with generalized myasthenia gravis.[4] |
| June 2024 |
FDA approves VYVGART Hytrulo for adults with chronic inflammatory demyelinating polyneuropathy.[5] |
| 2023-2024 |
Argenx expands commercialization in the United States, Europe, Japan and other major markets. |
The initial gMG label was limited to anti-AChR antibody-positive patients. The product’s commercial opportunity has broadened through the subcutaneous formulation and CIDP indication.
How large is the efgartigimod alfa-fcab market?
Efgartigimod addresses two rare autoimmune markets with substantial treatment intensity.
Generalized myasthenia gravis affects a relatively small patient population but requires chronic management, often involving corticosteroids, immunosuppressants, intravenous immunoglobulin, plasma exchange, complement inhibition, or B-cell depletion. Commercial value depends less on total prevalence than on the number of actively treated, refractory, and antibody-positive patients.
CIDP expands the addressable market. CIDP treatment has historically relied heavily on intravenous immunoglobulin, corticosteroids and plasma exchange. A subcutaneous FcRn inhibitor can compete for patients who require recurring maintenance therapy and may reduce dependence on infusion-based immunoglobulin treatment.
Main demand drivers
- Earlier use in treatment algorithms as neurologists gain experience with FcRn inhibition.
- Switching from intravenous VYVGART to VYVGART Hytrulo.
- Use in patients with inadequate disease control on conventional immunosuppression.
- CIDP adoption among patients seeking an alternative to intravenous immunoglobulin.
- Home or office-based administration through the subcutaneous presentation.
- Expansion of reimbursement and specialty-pharmacy access.
- International regulatory approvals and local pricing agreements.
Principal commercial constraints
- High annual treatment cost and prior-authorization requirements.
- Need for repeat treatment cycles rather than a one-time course.
- Competition with established therapies that have broader physician familiarity.
- Variable patient response and the need to monitor clinical benefit.
- Potential payer preference for lower-cost immunoglobulin or competing biologics.
- Limited diversification of argenx revenue outside efgartigimod.
What has been the financial trajectory of VYVGART?
Efgartigimod has produced one of the fastest commercial ramps among recently launched immunology biologics. Argenx reported product net sales of approximately $472 million in 2022, its first full commercial year, and approximately $1.2 billion in 2023.[1] The company reported approximately $2.2 billion in 2024 product net sales, reflecting continued gMG growth and the addition of CIDP revenue.[2]
| Fiscal year |
Approximate efgartigimod-related product sales |
Commercial interpretation |
| 2021 |
Initial launch period |
U.S. VYVGART approval in December |
| 2022 |
$472 million |
First full year of commercial availability |
| 2023 |
$1.2 billion |
Broad gMG adoption and launch of Hytrulo |
| 2024 |
Approximately $2.2 billion |
Continued gMG expansion plus CIDP launch |
| 2025 outlook |
Company guidance indicated continued high growth |
Driven by CIDP, Hytrulo conversion and geographic expansion |
Efgartigimod accounts for virtually all of argenx’s commercial revenue. The company’s financial profile therefore has unusually high product concentration. Strong sales growth has supported operating leverage, but sales and marketing investment remains substantial because argenx is building a global specialty commercial organization rather than relying entirely on a partner network.
What determines future revenue growth?
The most important revenue variable is treated-patient expansion. Pricing is relevant, but volume and treatment persistence are more significant because efgartigimod is used in recurring cycles. Revenue can rise through:
- New patient starts.
- More frequent or sustained treatment in appropriate patients.
- Conversion from IV VYVGART to Hytrulo.
- CIDP penetration.
- New geographic approvals.
- Label expansion into additional autoimmune diseases.
The CIDP launch provides the largest near-term indication expansion. It also changes the competitive frame because treatment decisions may be compared with immunoglobulin replacement rather than only with other gMG biologics.
How does efgartigimod compare with competing FcRn drugs?
The FcRn class has become a major competitive category in antibody-mediated autoimmune disease.
| Product |
Active ingredient |
Company |
Administration |
Key approved or commercial indication as of mid-2024 |
| VYVGART |
Efgartigimod alfa-fcab |
argenx |
Intravenous |
Generalized myasthenia gravis |
| VYVGART Hytrulo |
Efgartigimod alfa plus hyaluronidase |
argenx |
Subcutaneous |
Generalized myasthenia gravis and CIDP |
| RYSTIGGO |
Rozanolixizumab-noli |
UCB |
Subcutaneous |
Generalized myasthenia gravis |
| IMAAVY |
Nipocalimab |
Johnson & Johnson |
Not yet approved in the United States as of mid-2024 |
Clinical-stage FcRn program |
RYSTIGGO is the closest approved pharmacologic competitor in gMG. It is administered subcutaneously and can compete directly with Hytrulo on convenience, treatment cycle, physician preference and payer positioning.[6]
Efgartigimod has several commercial advantages. It entered the U.S. market before rozanolixizumab, has a substantial installed patient base, has both IV and subcutaneous presentations, and has entered CIDP. Its principal disadvantage is that much of its value depends on sustained disease control and recurring administration rather than a short treatment course.
What patents and exclusivity protect efgartigimod alfa-fcab?
Efgartigimod is protected by a layered biologic patent estate rather than by a single small-molecule patent. The relevant protection categories include:
- Fc-fragment composition and engineered FcRn-binding properties.
- Antibody and IgG reduction mechanisms.
- Dosing schedules and treatment cycles.
- Formulations for intravenous administration.
- Subcutaneous formulations.
- Combination products containing efgartigimod and recombinant human hyaluronidase.
- Manufacturing, purification and pharmaceutical composition claims.
- Method-of-use claims for autoimmune diseases.
The FDA does not treat VYVGART like a conventional small-molecule product in the Orange Book. Biologic reference-product information is primarily associated with the Purple Book, while patents are disclosed through patent-owner filings, regulatory submissions, and company intellectual-property records.[7]
What is the biologic exclusivity period for VYVGART?
Under the Biologics Price Competition and Innovation Act, a reference biologic receives 12 years of reference-product exclusivity from first licensure, subject to statutory rules and FDA determinations. For VYVGART, the first U.S. approval occurred on December 17, 2021. The statutory reference-product exclusivity period therefore runs into December 2033, although patent rights may extend beyond or expire before that date depending on the specific claim and any patent-term adjustment.[3][7]
The key distinction is:
- Regulatory exclusivity limits when FDA may approve a biosimilar.
- Patent rights determine whether a biosimilar or follow-on product can lawfully launch.
- Patent litigation and settlement agreements may change the practical launch date.
How strong is the efgartigimod patent estate?
The estate is commercially meaningful because it combines biologic reference exclusivity with multiple technical claim categories. The strongest protection is likely to come from claims that cover the engineered FcRn antagonist itself, clinically validated dosing regimens, and the Hytrulo combination.
Formulation and administration claims are important because a competitor may be able to develop a different FcRn antagonist but still face barriers if it seeks to reproduce the same delivery architecture. The subcutaneous product also creates a separate value layer around hyaluronidase-enabled delivery, concentration, injection volume, stability and dosing.
Patent strength is not equivalent to patent count. Composition claims generally provide broader protection than narrow method-of-use or formulation claims. Method-of-use claims can still have high commercial value when the drug is administered for a limited number of well-defined indications.
When does efgartigimod lose exclusivity and when could biosimilar entry occur?
The principal U.S. timing points are:
| Protection type |
Relevant date or period |
| First U.S. approval |
December 17, 2021 |
| Four-year biosimilar submission restriction |
December 17, 2025, subject to statutory interpretation and FDA treatment of the reference product |
| Twelve-year reference-product exclusivity |
December 17, 2033 |
| Patent protection |
Depends on individual patent expiration, terminal disclaimers, patent-term adjustment and any patent-term extension |
| Practical biosimilar launch |
Could be later than statutory exclusivity if unexpired patents remain or a settlement limits entry |
A biosimilar applicant may file an abbreviated application after the four-year period, but FDA approval cannot generally become effective until the reference product’s 12-year exclusivity period has elapsed. The patent dance and litigation process can start before approval, creating potential launch dates that depend on patent settlements.
Biosimilar risk is lower in the near term than generic risk for a small molecule because efgartigimod is a complex engineered biologic. Development requires analytical comparability, pharmacokinetic and immunogenicity work, manufacturing capability and commercial-scale supply. Those barriers reduce the number of credible entrants but do not eliminate long-term competition.
Are there Paragraph IV challenges to VYVGART?
Paragraph IV certifications apply to patents listed for approved small-molecule drugs under the Hatch-Waxman system. VYVGART is a biologic, so a conventional Paragraph IV generic challenge is not the primary pathway.
The relevant challenge model is a biosimilar application under section 351(k) of the Public Health Service Act, combined with patent litigation under the BPCIA. A company seeking to compete with efgartigimod would likely contest patents through the BPCIA patent-exchange process, declaratory litigation, validity challenges, or an agreement establishing a later entry date.
No major public U.S. biosimilar litigation or commercial settlement involving efgartigimod had been disclosed through mid-2024. That status can change as the four-year submission restriction approaches.
What FDA and Orange Book issues affect VYVGART?
VYVGART has no conventional Orange Book framework comparable to products such as branded tablets or injectable small molecules. The relevant regulatory records are:
- FDA biologic license application approval letters.
- VYVGART and VYVGART Hytrulo prescribing information.
- Purple Book reference-product and biosimilar records.
- Patent information supplied in connection with biologic competition.
- FDA exclusivity determinations.
The FDA approved VYVGART under a biologics license application. VYVGART Hytrulo is a separate presentation that adds recombinant human hyaluronidase PH20 and has its own manufacturing, labeling and product-quality considerations.[3][4][5]
What manufacturing and intellectual-property barriers affect competitors?
Manufacturing is a meaningful barrier to entry. Efgartigimod requires production of a recombinant Fc fragment with controlled structural attributes, impurity levels, potency and aggregate profile. The Hytrulo product adds a second biologic component and requires consistent co-formulation or co-administration performance.
Potential barriers include:
- Cell-line and expression-system development.
- Control of glycosylation and product heterogeneity.
- Purification and aggregation control.
- Stability of the final drug product.
- Scalable subcutaneous formulation.
- Compatibility with hyaluronidase delivery.
- Immunogenicity assessment.
- Global manufacturing validation and cold-chain distribution.
These barriers support a durable franchise even after regulatory exclusivity ends. They do not prevent competition from alternative FcRn molecules, which may avoid efgartigimod-specific patents by using different sequences, binding profiles or formulations.
What litigation and settlement risks affect efgartigimod?
The most important future disputes would likely involve:
- Biosimilar patent litigation under the BPCIA.
- Validity or infringement challenges to FcRn-binding and composition patents.
- Disputes over Hytrulo formulation and hyaluronidase-related claims.
- Patent-term calculations and terminal-disclaimer issues.
- International opposition or revocation proceedings.
- Licensing disputes involving regional commercialization rights.
A settlement could preserve substantial value even if it permits an early biosimilar launch. The commercial result would depend on the agreed entry date, authorized-generic or biosimilar economics, royalty terms, and scope of the released patents.
What licensing deals support efgartigimod commercialization?
Argenx has retained significant control over efgartigimod commercialization in major markets while using regional arrangements and distribution infrastructure where appropriate. The company’s business model emphasizes direct commercial execution in the United States and key international markets.
The commercial value of efgartigimod increases when argenx retains product economics rather than transferring them to a large pharmaceutical partner. The tradeoff is higher selling, general and administrative expense and greater execution risk. Licensing or co-commercialization could become more relevant in markets where regulatory access, reimbursement, or local distribution requires a partner.
What generic entry risks exist for VYVGART?
The near-term threat is not a conventional generic. The principal risks are:
- Competing FcRn inhibitors with differentiated dosing.
- Payer-led switching to lower-cost therapies.
- Biosimilar entry after the exclusivity and patent periods.
- Follow-on products with more convenient self-administration.
- Combination regimens that reduce treatment frequency.
- Clinical preference for therapies with broader antibody or serologic coverage.
- Price pressure as the FcRn class expands.
A biosimilar could face a slower uptake curve than a generic because physicians and payers may distinguish between reference and biosimilar biologics, particularly in rare autoimmune diseases. Interchangeability, substitution rules, specialty-pharmacy contracting and physician confidence will determine the commercial impact.
How does VYVGART compare with RYSTIGGO and immunoglobulin therapy?
VYVGART competes with RYSTIGGO on mechanism, route, dosing convenience and clinical familiarity. It competes with intravenous immunoglobulin and subcutaneous immunoglobulin on treatment tradition, supply availability, reimbursement and physician experience.
| Criterion |
VYVGART/VYVGART Hytrulo |
RYSTIGGO |
Immunoglobulin therapy |
| Mechanism |
FcRn antagonism |
FcRn antagonism |
Passive IgG replacement and immunomodulation |
| Administration |
IV or subcutaneous |
Subcutaneous |
IV or subcutaneous |
| gMG use |
Approved |
Approved |
Established but often off-label or supportive |
| CIDP use |
Hytrulo approved |
Not the same approved CIDP position as of mid-2024 |
Established treatment category |
| Supply constraints |
Biologic manufacturing |
Biologic manufacturing |
Plasma supply and fractionation capacity |
| Commercial risk |
Newer class, high product concentration |
Direct FcRn competition |
Price, supply and payer controls |
For CIDP, immunoglobulin supply and treatment burden create an opening for VYVGART Hytrulo. The product’s long-term position will depend on comparative effectiveness, durability, patient preference and payer economics.
What is the investment and revenue exposure to efgartigimod?
Efgartigimod is both argenx’s growth engine and its central concentration risk. The drug generates nearly all product revenue, so the company’s valuation is highly sensitive to:
- Net patient additions.
- Duration of therapy.
- CIDP uptake.
- Hytrulo conversion.
- U.S. reimbursement.
- International pricing.
- FcRn competition.
- Clinical trial outcomes in new indications.
- Patent and biosimilar timing.
The revenue trajectory is favorable while penetration remains low and the label expands. The risk profile changes as the product matures. Growth will increasingly depend on maintaining treatment share, defending price, and adding indications rather than simply converting an untreated population.
Key Takeaways
- Efgartigimod alfa-fcab is marketed as VYVGART and VYVGART Hytrulo by argenx.
- U.S. approvals cover generalized myasthenia gravis, with VYVGART Hytrulo also approved for CIDP.
- Product sales rose from approximately $472 million in 2022 to $1.2 billion in 2023 and approximately $2.2 billion in 2024.
- The subcutaneous Hytrulo formulation is central to administration convenience, CIDP expansion and commercial durability.
- VYVGART competes directly with UCB’s RYSTIGGO and indirectly with immunoglobulin, complement inhibitors and B-cell therapies.
- Conventional Paragraph IV challenges do not apply because VYVGART is a biologic; future competition will use the BPCIA biosimilar pathway.
- The statutory U.S. reference-product exclusivity period extends to December 2033 based on the December 17, 2021 first approval.
- Patent protection is layered across composition, FcRn binding, dosing, formulations, Hytrulo delivery and manufacturing.
- Argenx’s revenue concentration creates high upside from continued adoption and high downside from competitive, regulatory or reimbursement disruption.
FAQs
Can efgartigimod alfa-fcab be used for CIDP?
VYVGART Hytrulo is FDA-approved for adults with CIDP. The approval materially expands the product’s addressable market beyond generalized myasthenia gravis.[5]
Is VYVGART a biosimilar or a reference biologic?
VYVGART is the reference biologic. Any future competitor would generally need to pursue the FDA’s 351(k) biosimilar pathway or submit a separate biologic license application.
Does VYVGART have an Orange Book patent listing?
VYVGART is regulated as a biologic, so the relevant exclusivity and competition records are associated with the Purple Book and BPCIA framework rather than the conventional Orange Book system for small-molecule drugs.
What is the biggest competitive threat to VYVGART?
The closest approved competitive threat is rozanolixizumab, marketed as RYSTIGGO. Broader long-term risk comes from additional FcRn inhibitors, alternative immunologic mechanisms and lower-cost follow-on biologics.
Why is VYVGART Hytrulo commercially important?
Hytrulo provides subcutaneous delivery, supports home or office administration, expands treatment options in CIDP and may convert patients from intravenous VYVGART. It also creates additional formulation and delivery patents around the commercial franchise.
References
- argenx SE. (2024). Annual report 2023 and full-year financial results.
- argenx SE. (2025). Full-year 2024 financial results and corporate update.
- U.S. Food and Drug Administration. (2021). FDA approves new treatment for adults with generalized myasthenia gravis.
- U.S. Food and Drug Administration. (2023). VYVGART Hytrulo prescribing information.
- U.S. Food and Drug Administration. (2024). FDA approves VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy.
- U.S. Food and Drug Administration. (2023). RYSTIGGO prescribing information.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
